Many had neoadjuvant therapy, still no difference between standard or extended lymphadenectomy for muscle-invasive bladder cancer. So, it seems more is not better.
Adding Inavolisib to CKD4/6 inhibitor and AI improved progression-free survival (almost doubled 15 vs 7m) but toxicity was higher still in the single digits (hyperglycemia, diarrhea, stomatitis… all less than 6% G3/4).
10-year survival data from Checkmate 067 on Ipi+Nivo, Nivo and Ipi alone in met-melanoma. The OS was twice as long in the Ipi+Nivo group compared to Nivo alone. Of note this was with Nivo-1 + Ipi-3, and most of us use the more tolerable Nivo-3 + Ipi-1 dosing based on Checkmate 511. This remains the SOC for good PFS met-melanoma in my opinion.
Growth differentiation factor 15 seems to be a driver in cancer cachexia. Ponsegromab targets this pathway and shows a meaningful improvement in weight, appetite and activity level in patients with a high level of this protein. It is fantastic to see a study like this and I’m excited to use this drug when available.
Imatinib cessation after a good response in met-GIST should not be considered. Based on this study’s results patients should be left on therapy until disease progression or toxicity issues.
Enhertu shows promising activity in met-BTC’s that are HER2-pos but also in HER2-low. Using this in HER2-low would be off label but something to consider after SOC therapy.
Based on these findings, Carbo/Taxol+Pembro is an active regimen in met-HNC and an option for those patients who are not good candidates for 5FU based therapy.
TIP will likely become the established salvage therapy for GCT’s if this study’s findings are confirmed in the ongoing Phase III TIGER trial.
I guess scalp cooling does have some objective evidence that it works. Still the expense and time constraints will need to be considered.
Protons vs IMRT for localized prostate cancer showed no difference in outcome or quality of life. There will be longer f/u and other endpoints studied but the take-home message is that protons are not significantly better than photons.